Smart Nanoparticles Combine Gene Silencing and Sound Waves to Fight Melanoma

Melanoma accounts for roughly 90% of skin cancer deaths, and existing therapies face persistent challenges including drug resistance, limited immune activation, and poor deep-tissue drug penetration. Sonodynamic therapy (SDT), which uses ultrasound-activated sonosensitizers to produce cytotoxic ROS, offers a tissue-penetrating alternative to photodynamic therapy, but its efficacy is blunted by post-treatment lactate accumulation that suppresses immune cell function in the tumor microenvironment.

To address this, the research team engineered si-Ce6@tLyP-1 NPs — lipid-based, phase-transition nanoparticles whose liquid perfluoropentane (PFP) core encapsulates Chlorin e6 (Ce6) and electrostatically adsorbs FTO siRNA on the surface. The outer shell is decorated with the tLyp-1 peptide (CGNKRTR), which binds neuropilin-1 (NRP-1) overexpressed on B16-F10 melanoma cells, conferring active tumor targeting and deep-tissue penetration. Particles were prepared by a filming-rehydration and acoustic vibration protocol, yielding spherical, uniform nanoparticles averaging ~295 nm with a zeta potential of −31 mV after siRNA loading. Encapsulation efficiency for Ce6 reached 76.2%, and complete siRNA loading was achieved at a 1:8 siRNA-to-nanoparticle mass ratio.

Upon systemic administration and tumor accumulation, focused ultrasound triggered liquid-to-gas phase transition of PFP, releasing Ce6 and siRNA (ultrasound-targeted microbubble destruction, UTMD effect). Ce6 generated singlet oxygen and other ROS that induced apoptosis and immunogenic cell death (ICD) in tumor cells, evidenced by calreticulin (CRT) and HMGB1 release. ICD signals drove dendritic cell maturation and subsequent T lymphocyte activation. Concurrently, the ultrasound-enhanced intracellular delivery of FTO siRNA silenced the FTO gene, suppressing expression of glycolytic enzymes (HK1, GLUT1, PKM) and significantly reducing lactate secretion by tumor cells — removing the metabolic immunosuppressive barrier that would otherwise blunt T cell function post-SDT.

In vitro and in B16-F10 murine melanoma models, the combined si-Ce6@tLyP-1 NPs plus ultrasound regimen demonstrated superior tumor cell cytotoxicity, increased dendritic cell maturation, and greater CD8+ T cell infiltration and effector activity compared to SDT alone, siRNA alone, or untargeted nanoparticle controls. Nanoparticle stability was confirmed over seven days in PBS and serum-containing medium. The seven-day stability data and SOSG probe singlet oxygen generation assays validated both the structural integrity and the sonodynamic functionality of the platform.

This study presents a compelling proof-of-concept for targeting an epigenetic metabolic regulator (FTO) in combination with physical energy-based immunotherapy. The multimodal platform elegantly addresses two key SDT failure modes — insufficient immune activation and lactate-mediated immunosuppression — within a single injectable formulation. Caveats include reliance on a syngeneic murine model (B16-F10) that may not fully recapitulate human melanoma heterogeneity, limited data on systemic toxicity and off-target siRNA effects, and the need for external ultrasound equipment to trigger drug release.